Scientists are designing molecules, changing cell states and testing ways to restore damaged tissue. Follow the programmes and the evidence they produce.
Discovery can move quickly. Human experiments test whether a treatment does what researchers intended.
Read the mechanism, development history and human evidence.
Life Biosciences
ER-100 is an OSK partial-reprogramming gene therapy in an open-label Phase 1 eye study. Its developer reports 56-day safety observations in three glaucoma patients and exploratory visual-field changes in two.
Insilico Medicine
Rentosertib connects AI-assisted target selection and molecular design with published lung-disease trial results. A September 2026 analysis examined ageing clocks in stored samples. The developer also announced first dosing in a larger Phase 3 study; the medicine remains experimental.
Academic collaborations at Memorial Sloan Kettering and Cold Spring Harbor Laboratory
Researchers have engineered T cells to recognise uPAR, a surface protein associated with senescence. Mouse studies test whether clearing these cells improves metabolism and intestinal function.
Broad Institute, MIT and academic collaborators
A mouse study uses liver-directed mRNA to supply immune signals. The research tests a temporary change in immune function.
A first dose, a published result or a programme ending. Each development has a date and a source.
Read the development recordNewLimit reports first large-animal models, additional functional reprogramming payloads and scaled manufacturing. Full preclinical datasets were not provided in the update.
Company reports day-56 tolerability in three glaucoma participants, preliminary visual-field changes in two and approval to escalate dose. No controlled efficacy conclusion.
On 1 October the developer announced a planned 8 October presentation of early glaucoma-cohort findings. The subsequent results are recorded separately below.
Models of cells, designed proteins and the experiments that test their predictions.
Proteomic ageing clocks predict age or health-related outcomes from proteins measured in blood. Their readings can change during disease treatment, making interpretation particularly important.
Read article
Mouse, dog and killifish studies can compare biological-age measurements with later survival. The evidence is strongest for prediction; the value of treatment-induced clock changes is less certain.
Read article
An automated laboratory becomes a learning system when measured results determine the next experiments. Cell-free protein synthesis and enzyme engineering show what these systems have achieved, how people contributed and which comparisons remain missing.
Read articleFollow AI biology, immune engineering and attempts to repair or replace damaged cells.
How researchers model cells, predict molecular behaviour, design proteins and choose experiments.
02Changing gene expression and cell state while preserving the function a tissue needs.
03Experiments that remove senescent cells or change the signals they release.
04Replacing lost tissue, growing cells and developing organs that can restore function.
05Getting an experimental treatment to the right cells, with enough control over its activity.
06The tests, endpoints and research frameworks used to judge biological and functional change.
07Drugs and experiments intended to restore cells’ recycling and protein-maintenance systems.
A study can measure a change in a molecule, a tissue or a person’s function. Who was studied, what was measured and how the result was obtained determine what it can tell us.
Programme histories keep published findings alongside company disclosures and trial records. Each source is identified so you can check it yourself.
Read the editorial method